• The health care system in Bulgaria faces unprecedented challenges trying to take control over the pandemic of COVID-19. • The existing national regulation in Bulgaria leads to delayed and difficult access to investigational drugs via compassionate use programs. • The COVID-19 pandemic will initiate a dialogue among health policy makers and BDA for the establishment of new health policy and clear national regulation due to higher demand for investigational drugs.